Safety and efficacy of addition of VEGFR and EGFR-family oral small-molecule tyrosine kinase inhibitors to cytotoxic chemotherapy in solid cancers: a systematic review and meta-analysis of randomized controlled trials

Funakoshi T, Latif A, Galsky MD

Record Status
This is a systematic review that meets the criteria for inclusion on DARE.

Bibliographic details

DOI
10.1016/j.ctrv.2014.02.004

Indexing Status
Subject indexing assigned by NLM

MeSH
Administration, Oral; Antineoplastic Combined Chemotherapy Protocols /adverse effects /therapeutic use; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions /epidemiology /etiology; Female; Humans; Male; Maximum Tolerated Dose; Neoplasms /drug therapy /mortality /pathology; Patient Safety; Protein Kinase Inhibitors /adverse effects /therapeutic use; Protein-Tyrosine Kinases /antagonists & inhibitors /therapeutic use; Randomized Controlled Trials as Topic; Receptor, Epidermal Growth Factor /drug effects /metabolism; Receptors, Vascular Endothelial Growth Factor /drug effects /metabolism; Risk Assessment; Treatment Outcome

AccessionNumber
12014021152

Date bibliographic record published
18/06/2014